تحميل
HKSEHealthcareDrug Manufacturers - Specialty & Generic
أحدث البيانات المتاحة
3.925 HK$
+0.075 HK$ · +1.95%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
أحدث البيانات المتاحة
3.925 HK$
+0.075 HK$ · +1.95%
تستخدم الأوقات اليومية المنطقة الزمنية HKT. قد تتأخر بيانات السوق.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
نطاق اليوم
السعر الحالي 3.925 HK$
نطاق 52 أسبوعًا
السعر الحالي 3.925 HK$
تستخدم الأوقات اليومية المنطقة الزمنية HKT. قد تتأخر بيانات السوق.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
نطاق اليوم
السعر الحالي 3.925 HK$
نطاق 52 أسبوعًا
السعر الحالي 3.925 HK$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
توزيعات نقدية سنوية معدلة للسهم الواحد.
0.2717 HK$
2025 سنة كاملة+50.9% منذ 2021
2026 سنة جزئية: 0.166 HK$
0.18 HK$
2,021
0.0411 HK$
2,022
0.1122 HK$
2,023
0.2717 HK$
2,025
0.166 HK$
2,026*
* سنة تقويمية جزئية ضمن سجل توزيعات الأرباح المتاح.
| الإجراء | تاريخ الاستحقاق | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
توزيعات الأرباح | 27 مايو 2026 | 0.166 HK$Annual | 28 مايو 2026 | 18 يونيو 2026 |
توزيعات الأرباح | 26 مايو 2025 | 0.2717 HK$Annual | 27 مايو 2025 | 22 يوليو 2025 |
توزيعات الأرباح | 24 مايو 2023 | 0.1122 HK$Annual | 25 مايو 2023 | 15 أغسطس 2023 |
توزيعات الأرباح | 14 يونيو 2022 | 0.0411 HK$Annual | 15 يونيو 2022 | 15 أغسطس 2022 |
توزيعات الأرباح | 28 مايو 2021 | 0.18 HK$Annual | 31 مايو 2021 | 26 يوليو 2021 |
استحقاق التوزيعات 27 مايو 2026
0.166 HK$
Annual
تاريخ التسجيل 28 مايو 2026 · تاريخ الدفع 18 يونيو 2026
استحقاق التوزيعات 26 مايو 2025
0.2717 HK$
Annual
تاريخ التسجيل 27 مايو 2025 · تاريخ الدفع 22 يوليو 2025
استحقاق التوزيعات 24 مايو 2023
0.1122 HK$
Annual
تاريخ التسجيل 25 مايو 2023 · تاريخ الدفع 15 أغسطس 2023
استحقاق التوزيعات 14 يونيو 2022
0.0411 HK$
Annual
تاريخ التسجيل 15 يونيو 2022 · تاريخ الدفع 15 أغسطس 2022
استحقاق التوزيعات 28 مايو 2021
0.18 HK$
Annual
تاريخ التسجيل 31 مايو 2021 · تاريخ الدفع 26 يوليو 2021
2359.HK
WuXi AppTec Co., Ltd.
202.6 HK$
-3.06%
1276.HK
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
47.14 HK$
-2.68%
6160.HK
BeOne Medicines AG
207 HK$
-2.82%
2269.HK
WuXi Biologics (Cayman) Inc.
52.35 HK$
-3.23%
3692.HK
Hansoh Pharmaceutical Group Company Limited
31.48 HK$
-2.18%
1801.HK
Innovent Biologics, Inc.
91.45 HK$
-1.24%
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Dimensional - Emerging Markets Core Equity 2 ETFDFEM109.37 ألف0.00%9.73 مليار USD0.39%39.58 US$-1.54%
Dimensional - Emerging Core Equity Market ETFDFAE74.86 ألف0.00%10.2 مليار USD0.29%39.02 US$-1.69%
Dimensional World ex U.S. Core Equity 2 ETFDFAX45.94 ألف0.00%12.37 مليار USD0.28%36.80 US$-0.76%
Dimensional - Emerging Markets Value ETFDFEV36.7 ألف0.00%2.2 مليار USD0.46%42.16 US$-1.47%
Vanguard Total International Stock ETFVXUS11 ألف—665.7 مليار USD0.05%84.10 US$-0.81%
Vanguard Total World Stock ETFVT8.53 ألف0.00%101.7 مليار USD0.06%158.73 US$-0.57%Dimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Value ETFDFEVVanguard Total International Stock ETFVXUSVanguard Total World Stock ETFVTالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.